Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targets in MPNs and potential therapeutics.

International review of cell and molecular biology - 1 Jan 2022

Levy Gabriel, Mambet Cristina, Pecquet Christian, Bailly Sarah, Havelange Violaine, Diaconu Carmen C, Constantinescu Stefan N

Abstract excerpt

Philadelphia-negative classical Myeloproliferative Neoplasms (MPNs), including Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), are clonal hemopathies that emerge in the hematopoietic stem cell (HSC) compartment. MPN driver mutations are restricted to specific exons (14 and 12) of Janus kinase 2 (JAK2), thrombopoietin receptor (MPL/TPOR) and calreticulin (CALR) genes, are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Mutation
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Share to Tumor Microenvironment

Source

Identifiers

PMID: 35153006
DOI: 10.1016/bs.ircmb.2021.06.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targets in MPNs and potential therapeutics.PMID 35153006Read ↗

Functional Consequences of Mutations in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.Semantic proximity Read ↗

Molecular pathogenesis of the myeloproliferative neoplasms.Semantic proximity Read ↗

Genetic basis and molecular profiling in myeloproliferative neoplasms.Semantic proximity Read ↗

Biology and therapeutic targeting of molecular mechanisms in MPNs.Semantic proximity Read ↗

Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.Semantic proximity Read ↗

Effect of mutation on diagnosis, risk stratification, and treatment decisions in Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.